Life Science companies have adopted a multi-track approach to cope with the current and anticipated drop in sales revenue, including; cutting costs and staff, expanding business in emerging markets, , re-calibrating business models, and research priorities ; using real world evidence and emphasizing a product's clinical, safety and economic impact to articulate their value proposition. Next to classic mergers and acquisitions (M&A) Strategic Alliances have proven to be a viable alternative in coping with these challenges.
